IL320303A - Treating peanut allergy with durable nanoparticles - Google Patents
Treating peanut allergy with durable nanoparticlesInfo
- Publication number
- IL320303A IL320303A IL320303A IL32030325A IL320303A IL 320303 A IL320303 A IL 320303A IL 320303 A IL320303 A IL 320303A IL 32030325 A IL32030325 A IL 32030325A IL 320303 A IL320303 A IL 320303A
- Authority
- IL
- Israel
- Prior art keywords
- administered
- timp
- ppe
- nsaid
- leukotriene modifier
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Claims (1)
1. The method of any one of claims 45-54, wherein the corticosteroid is administered 30 minutes prior to administration of TIMP-PPE. 56. The method of claim 45, wherein the NSAID is acetylsalicylic acid. 57. The method of any one of claims 45 and 56, wherein the NSAID is administered at a dose of about 0.05 mg, 0.1 mg, 0.5 mg, 1 mg, 2 mg, 4 mg, 5 mg, 10 mg, 25 mg, 50 mg, mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 300 mg, 325 mg, 3mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, 1000 mg, 1500 mg, or 2000 mg. 58. The method of any one of claims 45 or 56-57, wherein the NSAID is administered orally. 59. The method of any one of claims 45 or 56-58, wherein the NSAID is administered in a single dose or in multiple doses. 60. The method of any one of claims 45 or 56-59, wherein the NSAID is administered daily for two days and 60 minutes prior to administration of TIMP-PPE. 61. The method of claim 45, wherein the leukotriene modifier is montelukast. 62. The method of any one of claims 45 or 61, wherein the leukotriene modifier is administered at a dose of about 0.05 mg, 0.1 mg, 0.5 mg, 1 mg, 2 mg, 4 mg, 5 mg, 10 mg, mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg, 275 mg, 3mg, 325 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, 1000 mg, 1500 mg, or 20mg. 63. The method of any one of claims 45 or 61-62, wherein the leukotriene modifier is administered orally. 64. The method of any one of claims 45 or 61-63, wherein the leukotriene modifier is administered in a single dose or in multiple doses. 65. The method of any one of claims 45 or 61-64, wherein the leukotriene modifier is administered 12 hours prior, 45 minutes prior to and/or 12 hours after administration of TIMP-PPE. 66. Tolerizing immune modifying particles encapsulating peanut proteins (TIMP-PPE) for use in a method of treating peanut allergy in a subject, wherein the method comprises administering to the subject the TIMP-PPE, alone or in combination with one or more therapeutics, wherein TIMP-PPE is administered at a dose level of between about 0.001 mg/kg and 12 mg/kg.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263380173P | 2022-10-19 | 2022-10-19 | |
| US202363486812P | 2023-02-24 | 2023-02-24 | |
| PCT/US2023/077287 WO2024086706A1 (en) | 2022-10-19 | 2023-10-19 | Treatment of peanut allergy with tolerizing nanoparticles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL320303A true IL320303A (en) | 2025-06-01 |
Family
ID=88874653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL320303A IL320303A (en) | 2022-10-19 | 2023-10-19 | Treating peanut allergy with durable nanoparticles |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4604999A1 (en) |
| JP (1) | JP2025536294A (en) |
| KR (1) | KR20250080899A (en) |
| CN (1) | CN120282796A (en) |
| AU (1) | AU2023364203A1 (en) |
| IL (1) | IL320303A (en) |
| MX (1) | MX2025004548A (en) |
| TW (1) | TW202430207A (en) |
| WO (1) | WO2024086706A1 (en) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013131925A1 (en) | 2012-03-06 | 2013-09-12 | Highlife Sas | Treatment catheter member with encircling function |
| KR102233251B1 (en) * | 2013-04-03 | 2021-03-26 | 엔-폴드 엘엘씨 | Novel nanoparticle compositions |
| CN105555301B (en) | 2013-08-13 | 2021-04-16 | 西北大学 | Peptide-conjugated particles |
| EP3393514A4 (en) | 2015-12-23 | 2019-08-14 | Cour Pharmaceuticals Development Company Inc. | PARTICLES CONJUGATED BY COVALENCE OF THE POLYMER-ANTIGEN TYPE |
| JP6904959B2 (en) | 2016-01-04 | 2021-07-21 | クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド | Particles encapsulating a fusion protein containing a binding epitope |
| MX2023012257A (en) | 2021-04-16 | 2024-01-08 | Cour Pharmaceuticals Dev Company Inc | Method of tracking maintenance of immunological tolerance. |
| CN117813111A (en) * | 2021-04-16 | 2024-04-02 | 库尔制药开发公司 | Treating peanut allergy with tolerant nanoparticles |
-
2023
- 2023-10-19 IL IL320303A patent/IL320303A/en unknown
- 2023-10-19 JP JP2025521946A patent/JP2025536294A/en active Pending
- 2023-10-19 AU AU2023364203A patent/AU2023364203A1/en active Pending
- 2023-10-19 WO PCT/US2023/077287 patent/WO2024086706A1/en not_active Ceased
- 2023-10-19 TW TW112139979A patent/TW202430207A/en unknown
- 2023-10-19 CN CN202380080039.6A patent/CN120282796A/en active Pending
- 2023-10-19 EP EP23809854.5A patent/EP4604999A1/en active Pending
- 2023-10-19 KR KR1020257015765A patent/KR20250080899A/en active Pending
-
2025
- 2025-04-16 MX MX2025004548A patent/MX2025004548A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024086706A1 (en) | 2024-04-25 |
| KR20250080899A (en) | 2025-06-05 |
| CN120282796A (en) | 2025-07-08 |
| TW202430207A (en) | 2024-08-01 |
| EP4604999A1 (en) | 2025-08-27 |
| AU2023364203A1 (en) | 2025-05-15 |
| JP2025536294A (en) | 2025-11-05 |
| MX2025004548A (en) | 2025-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11344545B2 (en) | Use of levocetirizine and montelukast in the treatment of autoimmune disorders | |
| DK2303287T3 (en) | Antiallergic marine biopolymers | |
| JP2024174927A5 (en) | ||
| US9993512B2 (en) | Use of escin | |
| JPH05506007A (en) | Treatment of human retroviral infections with 2'3'-dideoxyinosine | |
| JP2009529502A5 (en) | ||
| EP3348273B1 (en) | Compositions based on xyloglucan and proteins for the treatment of intestinal disorders | |
| WO2014164285A2 (en) | Use of levocetirizine and montelukast in the treatment of vasculitis | |
| Lane | A steroid sparing effect of ketotifen in steroid‐dependent asthmatics | |
| JP2016512247A5 (en) | ||
| Carson et al. | Severe rhinitis medicamentosa successfully treated with Rhinolight® endonasal UV phototherapy | |
| CN114404409A (en) | A kind of medicine combination that can treat pain and its application | |
| JP2023527926A5 (en) | ||
| RU2065748C1 (en) | Method of treatment of chronic staphyloderma | |
| JP2023517295A5 (en) | ||
| CN101155581A (en) | Medicine and treatment for herpes simplex | |
| CN109528708A (en) | Application of the Kaempferol in preparation treatment rhinitis drug | |
| Strauss | Complications from Flu–an unnecessary evil! | |
| Cho et al. | Randomized, Double-Blind, Multicenter, Phase 3 Study of AG NPP709 Compared With Ivy Leaf Extract in Patients With Acute or Chronic Respiratory Symptoms | |
| Strauss | Complications from Flu-an unnecessary evil! How to treat and manage patients suffering from influenza in order to prevent unnecessary complications and adverse outcomes. | |
| CN111467357A (en) | Pharmaceutical composition and preparation method and application thereof | |
| Khangura | Considering the integration of cannabis into conventional chronic pain management strategies | |
| OA20662A (en) | Medicine based on extracts of six plants indicated for the treatment of covid-19. | |
| JPH11236402A (en) | Novel polysaccharide, antiviral agent and adjuvant for the polysaccharide | |
| Upendrababu | Red man syndrome |